Joshua Pinto Sells 8,048 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto sold 8,048 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $1.67, for a total transaction of $13,440.16. Following the completion of the transaction, the president now directly owns 76,952 shares in the company, valued at $128,509.84. This represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Neumora Therapeutics Trading Up 3.0 %

NASDAQ NMRA opened at $1.71 on Friday. Neumora Therapeutics, Inc. has a 12 month low of $1.60 and a 12 month high of $21.00. The company’s 50 day simple moving average is $4.47 and its 200 day simple moving average is $9.40.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NMRA shares. William Blair reissued an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $29.00 to $4.00 in a report on Thursday, January 2nd. Bank of America decreased their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Neumora Therapeutics during the fourth quarter valued at about $61,000. PNC Financial Services Group Inc. acquired a new position in shares of Neumora Therapeutics in the 4th quarter worth approximately $64,000. Quantbot Technologies LP acquired a new stake in Neumora Therapeutics during the fourth quarter valued at approximately $92,000. PEAK6 LLC bought a new stake in Neumora Therapeutics during the fourth quarter worth approximately $117,000. Finally, EntryPoint Capital LLC acquired a new position in Neumora Therapeutics in the fourth quarter worth approximately $135,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.